Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0MC3R
|
|||
Former ID |
DIB014796
|
|||
Drug Name |
Goxalapladib
|
|||
Synonyms |
Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide; 677116
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Discontinued in Phase 1 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C40H39F5N4O3
|
|||
Canonical SMILES |
COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C(=CC(=O)C5=C4N=CC=C5)CCC6=C(C(=CC=C6)F)F
|
|||
InChI |
1S/C40H39F5N4O3/c1-52-23-22-47-20-17-32(18-21-47)48(25-27-7-9-28(10-8-27)29-11-14-31(15-12-29)40(43,44)45)37(51)26-49-33(16-13-30-4-2-6-35(41)38(30)42)24-36(50)34-5-3-19-46-39(34)49/h2-12,14-15,19,24,32H,13,16-18,20-23,25-26H2,1H3
|
|||
InChIKey |
OBJKLVFDRLAGJI-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 412950-27-7
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Platelet-activating factor acetylhydrolase (PLA2G7) | Target Info | Modulator | [2] |
KEGG Pathway | Ether lipid metabolism | |||
Metabolic pathways | ||||
Biosynthesis of antibiotics | ||||
Pathway Interaction Database | Lissencephaly gene (LIS1) in neuronal migration and development | |||
WikiPathways | IL1 and megakaryotyces in obesity | |||
Synthesis, Secretion, and Deacylation of Ghrelin |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020582) | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020582) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.